BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30987862)

  • 21. RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML.
    Lichtenegger FS; Kondla I; Krempasky M; Weber AL; Herold T; Krupka C; Spiekermann K; Schneider S; Büchner T; Berdel WE; Wörmann BJ; Hiddemann W; Subklewe M
    Cancer Immunol Immunother; 2015 Dec; 64(12):1505-15. PubMed ID: 26377688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma.
    Chen Q; Han B; Meng X; Duan C; Yang C; Wu Z; Magafurov D; Zhao S; Safin S; Jiang C; Cai J
    Int J Cancer; 2019 Jul; 145(2):517-530. PubMed ID: 30613962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
    Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
    J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated lymphocyte specific protein 1 expression is involved in the regulation of leukocyte migration and immunosuppressive microenvironment in glioblastoma.
    Cao JY; Guo Q; Guan GF; Zhu C; Zou CY; Zhang LY; Cheng W; Wang GL; Cheng P; Wu AH; Li GY
    Aging (Albany NY); 2020 Jan; 12(2):1656-1684. PubMed ID: 32003759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
    DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
    Front Immunol; 2020; 11():1402. PubMed ID: 32765498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HVEM expression contributes to tumor progression and prognosis in human colorectal cancer.
    Inoue T; Sho M; Yasuda S; Nishiwada S; Nakamura S; Ueda T; Nishigori N; Kawasaki K; Obara S; Nakamoto T; Koyama F; Fujii H; Nakajima Y
    Anticancer Res; 2015 Mar; 35(3):1361-7. PubMed ID: 25750286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrative analysis of KIF4A, 9, 18A, and 23 and their clinical significance in low-grade glioma and glioblastoma.
    Cho SY; Kim S; Kim G; Singh P; Kim DW
    Sci Rep; 2019 Mar; 9(1):4599. PubMed ID: 30872592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment.
    Tejero R; Huang Y; Katsyv I; Kluge M; Lin JY; Tome-Garcia J; Daviaud N; Wang Y; Zhang B; Tsankova NM; Friedel CC; Zou H; Friedel RH
    EBioMedicine; 2019 Apr; 42():252-269. PubMed ID: 30952620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
    Ren S; Tian Q; Amar N; Yu H; Rivard CJ; Caldwell C; Ng TL; Tu M; Liu Y; Gao D; Ellison K; Suda K; Rozeboom L; Rivalland G; Mitchell P; Zhou C; Hirsch FR
    Lung Cancer; 2018 Nov; 125():115-120. PubMed ID: 30429008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling.
    Long S; Li M; Liu J; Yang Y; Li G
    Aging (Albany NY); 2020 Apr; 12(8):7112-7128. PubMed ID: 32310827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Classification of Glioblastoma Associated with Immune Checkpoints and Tumor Microenvironment based on Immunogenomic Profiling.
    Zheng P; Zhang X; Ren D; Bai Q
    Neurol India; 2024 Mar; 72(2):297-303. PubMed ID: 38691473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis in primary glioblastoma, IDH-wild-type.
    Sartori E; Langer R; Vassella E; Hewer E; Schucht P; Zlobec I; Berezowska S
    Oncol Rep; 2017 Oct; 38(4):2394-2400. PubMed ID: 28765916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel Foxp3-related immune prognostic signature for glioblastoma multiforme based on immunogenomic profiling.
    Guo XY; Zhang GH; Wang ZN; Duan H; Xie T; Liang L; Cui R; Hu HR; Wu Y; Dong JJ; He ZQ; Mou YG
    Aging (Albany NY); 2021 Jan; 13(3):3501-3517. PubMed ID: 33429364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epilysin is overexpressed in glioblastoma and related to clinical outcome of patients.
    Wang X; Zhang K; Chen X; Zhao C; Sun Z
    Med Oncol; 2015 Jan; 32(1):363. PubMed ID: 25429835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular cloning and characterization of TNFSF14 (LIGHT) and its receptor TNFRSF14 (HVEM) in guinea pig (Cavia porcellus).
    Li C; Chen S; Song J; Liu H; Gu W; Ai H; Zhao B; Zhang S
    Gene; 2013 Sep; 526(2):374-84. PubMed ID: 23732292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.
    Woroniecka K; Chongsathidkiet P; Rhodin K; Kemeny H; Dechant C; Farber SH; Elsamadicy AA; Cui X; Koyama S; Jackson C; Hansen LJ; Johanns TM; Sanchez-Perez L; Chandramohan V; Yu YA; Bigner DD; Giles A; Healy P; Dranoff G; Weinhold KJ; Dunn GP; Fecci PE
    Clin Cancer Res; 2018 Sep; 24(17):4175-4186. PubMed ID: 29437767
    [No Abstract]   [Full Text] [Related]  

  • 39. Murine Corneal Inflammation and Nerve Damage After Infection With HSV-1 Are Promoted by HVEM and Ameliorated by Immune-Modifying Nanoparticle Therapy.
    Edwards RG; Kopp SJ; Ifergan I; Shui JW; Kronenberg M; Miller SD; Longnecker R
    Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):282-291. PubMed ID: 28114589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
    Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
    J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.